PSU Profiles
Loading...
Keywords
Last Name
Institution

Chandra Belani

TitleProfessor
InstitutionCollege of Medicine
DepartmentMedicine
Address500 University Drive Hershey PA 17033
Phone7175311078
vCardDownload vCard

    Collapse Overview 
    Collapse overview
    PREFERRED TITLE/ROLE:

    Physician, Professor

    EDUCATION:

    Fellowship, Hematology, University of Maryland Medical System (Baltimore) (1988) Residency, Internal Medicine, North General Hospital (New York) (1985) Residency, Internal Medicine, University of Maryland Medical System (Baltimore) (1984) M.D., Sawai Man Sigh Medical College (1981)

    NARRATIVE:

    Dr. Belani directs translational and clinical investigations across all programs and the disease teams at the PSHCI. Dr. Belani is internationally renowned for his accomplishments in the area of lung cancer therapeutics and new drug development. His research efforts have led to changes in the treatment paradigms for lung cancer. Dr. Belani plays a key role in moving promising new discoveries for the treatment of all solid malignancies from the laboratory to the clinic and serves as a leader for early phase clinical trials at the PSHCI.


    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Zhang L, Belani CP, Zhang PH, Wang X, Yang L, Orlando M, Wu YL. Dynamic change of fatigue of pemetrexed maintenance treatment in the JMEN trial. Lung Cancer. 2018 Jan; 115:121-126. PMID: 29290253.
      View in: PubMed
    2. Pillai RN, Behera M, Owonikoko TK, Kamphorst AO, Pakkala S, Belani CP, Khuri FR, Ahmed R, Ramalingam SS. Comparison of the toxicity profile of PD-1 versus PD-L1 inhibitors in non-small cell lung cancer: A systematic analysis of the literature. Cancer. 2018 Jan 15; 124(2):271-277. PMID: 28960263.
      View in: PubMed
    3. Khorana AA, Vadhan-Raj S, Kuderer NM, Wun T, Liebman H, Soff G, Belani C, O'Reilly EM, McBane R, Eikelboom J, Damaraju CV, Beyers K, Dietrich F, Kakkar AK, Riess H, Peixoto RD, Lyman GH. Rivaroxaban for Preventing Venous Thromboembolism in High-Risk Ambulatory Patients with Cancer: Rationale and Design of the CASSINI Trial. Rationale and Design of the CASSINI Trial. Thromb Haemost. 2017 11 01; 117(11):2135-2145. PMID: 28933799.
      View in: PubMed
    4. Stoller R, Schmitz JC, Ding F, Puhalla S, Belani CP, Appleman L, Lin Y, Jiang Y, Almokadem S, Petro D, Holleran J, Kiesel BF, Ken Czambel R, Carneiro BA, Kontopodis E, Hershberger PA, Rachid M, Chen A, Chu E, Beumer JH. Phase I study of veliparib in combination with gemcitabine. Cancer Chemother Pharmacol. 2017 Sep; 80(3):631-643. PMID: 28770300.
      View in: PubMed
    5. Steuer CE, Behera M, Ernani V, Higgins KA, Saba NF, Shin DM, Pakkala S, Pillai RN, Owonikoko TK, Curran WJ, Belani CP, Khuri FR, Ramalingam SS. Comparison of Concurrent Use of Thoracic Radiation With Either Carboplatin-Paclitaxel or Cisplatin-Etoposide for Patients With Stage III Non-Small-Cell Lung Cancer: A Systematic Review. JAMA Oncol. 2017 Aug 01; 3(8):1120-1129. PMID: 27978552.
      View in: PubMed
    6. Dougall AL, Swanson J, Kyutoku Y, Belani CP, Baum A. Posttraumatic Symptoms, Quality of Life, and Survival among Lung Cancer Patients. J Appl Biobehav Res. 2017 Sep; 22(3). PMID: 28966544.
      View in: PubMed
    7. Wan Y, Cheng G, Liu X, Hao SJ, Nisic M, Zhu CD, Xia YQ, Li WQ, Wang ZG, Zhang WL, Rice SJ, Sebastian A, Albert I, Belani CP, Zheng SY. Rapid magnetic isolation of extracellular vesicles via lipid-based nanoprobes. Nat Biomed Eng. 2017; 1. PMID: 28966872.
      View in: PubMed
    8. Belani CP, Chakraborty BC, Modi RI, Khamar BM. A randomized trial of TLR-2 agonist CADI-05 targeting desmocollin-3 for advanced non-small-cell lung cancer. Ann Oncol. 2017 02 01; 28(2):298-304. PMID: 27831503.
      View in: PubMed
    9. Higgins KA, O'Connell K, Liu Y, Gillespie TW, McDonald MW, Pillai RN, Patel KR, Patel PR, Robinson CG, Simone CB, Owonikoko TK, Belani CP, Khuri FR, Curran WJ, Ramalingam SS, Behera M. National Cancer Database Analysis of Proton Versus Photon Radiation Therapy in Non-Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys. 2017 01 01; 97(1):128-137. PMID: 27979443.
      View in: PubMed
    10. Zheng H, Liu X, Zhang J, Rice SJ, Wagman M, Kong Y, Zhu L, Zhu J, Joshi M, Belani CP. Expression of PD-1 on CD4+ T cells in peripheral blood associates with poor clinical outcome in non-small cell lung cancer. Oncotarget. 2016 Aug 30; 7(35):56233-56240. PMID: 27191652.
      View in: PubMed
    11. Ardizzoni A, Tiseo M, Boni L, Di Maio M, Buffoni L, Belvedere O, Grossi F, D'Alessandro V, de Marinis F, Barbera S, Caroti C, Favaretto A, Cortinovis D, Morrica B, Tixi L, Ceschia T, Parisi S, Ricardi U, Grimaldi A, Loreggian L, Navarria P, Huber RM, Belani C, Brunsvig PF, Scagliotti GV, Scolaro T. Randomized phase III PITCAP trial and meta-analysis of induction chemotherapy followed by thoracic irradiation with or without concurrent taxane-based chemotherapy in locally advanced NSCLC. Lung Cancer. 2016 10; 100:30-37. PMID: 27597278.
      View in: PubMed
    12. Joshi M, Millis SZ, Arguello D, Holder SL, Lamm D, Reddy S, Belani C, Drabick JJ, Vogelzang NJ. Molecular Characterization of Bladder Cancer in Smokers versus Nonsmokers. Eur Urol Focus. 2016 Jun 24. PMID: 28753770.
      View in: PubMed
    13. Belani CP, Dahlberg SE, Rudin CM, Fleisher M, Chen HX, Takebe N, Velasco MR, Tester WJ, Sturtz K, Hann CL, Shanks JC, Monga M, Ramalingam SS, Schiller JH. Vismodegib or cixutumumab in combination with standard chemotherapy for patients with extensive-stage small cell lung cancer: A trial of the ECOG-ACRIN Cancer Research Group (E1508). Cancer. 2016 Aug 01; 122(15):2371-8. PMID: 27163943; PMCID: PMC4956531 [Available on 08/01/17].
    14. Wang H, Liu X, Rice SJ, Belani CP. Pulmonary Rehabilitation in Lung Cancer. PM R. 2016 Oct; 8(10):990-996. PMID: 27060645.
      View in: PubMed
    15. Gerber DE, Spigel DR, Giorgadze D, Shtivelband M, Ponomarova OV, Shan JS, Menander KB, Belani CP. Docetaxel Combined With Bavituximab in Previously Treated, Advanced Nonsquamous Non-Small-Cell Lung Cancer. Clin Lung Cancer. 2016 05; 17(3):169-76. PMID: 27265742.
      View in: PubMed
    16. Liu X, Rice SJ, Jamis-Dow CA, Abendroth C, Ali S, Almokadem S, Belani CP. A patient with complex multiple genomic ALK alterations. Thorax. 2016 Apr; 71(4):383-5. PMID: 26839360.
      View in: PubMed
    17. Rice SJ, Miller B, Wagman M, Jamorabo DS, Liu X, Belani CP. Clinical Approaches to Immunotherapy in Non-Small Cell Lung Cancer: Current and Future Perspectives. Curr Mol Pharmacol. 2016; 9(3):183-195. PMID: 26177648.
      View in: PubMed
    18. Liu X, Belani CP. Editorial (Thematic Issue: Clinical Advances in Immuno-oncology - Progress Towards Selective Cure). Curr Mol Pharmacol. 2016; 9(3):182. PMID: 26177639.
      View in: PubMed
    19. Behera M, Pillai RN, Owonikoko TK, Kim S, Steuer C, Chen Z, Saba NF, Belani CP, Khuri FR, Ramalingam SS. Bevacizumab in Combination with Taxane versus Non-Taxane Containing Regimens for Advanced/Metastatic Nonsquamous Non-Small-Cell Lung Cancer: A Systematic Review. J Thorac Oncol. 2015 Aug; 10(8):1142-7. PMID: 26200267.
      View in: PubMed
    20. Rice SJ, Liu X, Miller B, Joshi M, Zhu J, Caruso C, Gilbert C, Toth J, Reed M, Rassaei N, Das A, Barochia A, El-Bayoumy K, Belani CP. Proteomic profiling of human plasma identifies apolipoprotein E as being associated with smoking and a marker for squamous metaplasia of the lung. Proteomics. 2015 Sep; 15(18):3267-77. PMID: 26058877.
      View in: PubMed
    21. Xiang D, Yuan Y, Chen L, Liu X, Belani C, Cheng H. Niclosamide, an anti-helminthic molecule, downregulates the retroviral oncoprotein Tax and pro-survival Bcl-2 proteins in HTLV-1-transformed T lymphocytes. Biochem Biophys Res Commun. 2015 Aug 14; 464(1):221-228. PMID: 26116531; PMCID: PMC4580622.
    22. Niu G, Zhang H, Liu D, Chen L, Belani C, Wang HG, Cheng H. Tid1, the Mammalian Homologue of Drosophila Tumor Suppressor Tid56, Mediates Macroautophagy by Interacting with Beclin1-containing Autophagy Protein Complex. J Biol Chem. 2015 Jul 17; 290(29):18102-10. PMID: 26055714; PMCID: PMC4505055.
    23. Owonikoko TK, Dahlberg SE, Khan SA, Gerber DE, Dowell J, Moss RA, Belani CP, Hann CL, Aggarwal C, Ramalingam SS. A phase 1 safety study of veliparib combined with cisplatin and etoposide in extensive stage small cell lung cancer: A trial of the ECOG-ACRIN Cancer Research Group (E2511). Lung Cancer. 2015 Jul; 89(1):66-70. PMID: 25985977; PMCID: PMC4539011.
    24. Aronson KR, Wagstaff DA, Farace E, Muscat J, Belani C, Almokadem S, Fossum T. A week in the life of lung cancer survivors: Daily reports of stress, worry, mood, and symptoms. J Health Psychol. 2016 Oct; 21(10):2269-82. PMID: 25845832.
      View in: PubMed
    25. Varlotto JM, Yao AN, DeCamp MM, Ramakrishna S, Recht A, Flickinger J, Andrei A, Reed MF, Toth JW, Fizgerald TJ, Higgins K, Zheng X, Shelkey J, Medford-Davis LN, Belani C, Kelsey CR. Nodal stage of surgically resected non-small cell lung cancer and its effect on recurrence patterns and overall survival. Int J Radiat Oncol Biol Phys. 2015 Mar 15; 91(4):765-73. PMID: 25752390.
      View in: PubMed
    26. Joshi M, Rice SJ, Liu X, Miller B, Belani CP. Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer. PLoS One. 2015; 10(2):e0118210. PMID: 25706985; PMCID: PMC4338247.
    27. Joshi M, Rizvi SM, Belani CP. Afatinib for the treatment of metastatic non-small cell lung cancer. Cancer Manag Res. 2015; 7:75-82. PMID: 25733926; PMCID: PMC4340466.
    28. Ramalingam SS, Shtivelband M, Soo RA, Barrios CH, Makhson A, Segalla JG, Pittman KB, Kolman P, Pereira JR, Srkalovic G, Belani CP, Axelrod R, Owonikoko TK, Qin Q, Qian J, McKeegan EM, Devanarayan V, McKee MD, Ricker JL, Carlson DM, Gorbunova VA. Randomized phase II study of carboplatin and paclitaxel with either linifanib or placebo for advanced nonsquamous non-small-cell lung cancer. J Clin Oncol. 2015 Feb 10; 33(5):433-41. PMID: 25559798.
      View in: PubMed
    29. Appleman LJ, Balasubramaniam S, Parise RA, Bryla C, Redon CE, Nakamura AJ, Bonner WM, Wright JJ, Piekarz R, Kohler DR, Jiang Y, Belani CP, Eiseman J, Chu E, Beumer JH, Bates SE. A phase i study of DMS612, a novel bifunctional alkylating agent. Clin Cancer Res. 2015 Feb 15; 21(4):721-9. PMID: 25467180; PMCID: PMC4755291.
    30. Jiang Y, Mackley HB, Kimchi ET, Zhu J, Gusani N, Kaifi J, Staveley-O'Carroll KF, Belani CP. Phase I dose escalation study of capecitabine and erlotinib concurrent with radiation in locally advanced pancreatic cancer. Cancer Chemother Pharmacol. 2014 Jul; 74(1):205-10. PMID: 24908435.
      View in: PubMed
    31. Vasekar M, Liu X, Zheng H, Belani CP. Targeted immunotherapy for non-small cell lung cancer. World J Clin Oncol. 2014 May 10; 5(2):39-47. PMID: 24829850; PMCID: PMC4014795.
    32. Joshi M, Liu X, Belani CP. Taxanes, past, present, and future impact on non-small cell lung cancer. Anticancer Drugs. 2014 May; 25(5):571-83. PMID: 24463482.
      View in: PubMed
    33. Belani CP, Yamamoto N, Bondarenko IM, Poltoratskiy A, Novello S, Tang J, Bycott P, Niethammer AG, Ingrosso A, Kim S, Scagliotti GV. Randomized phase II study of pemetrexed/cisplatin with or without axitinib for non-squamous non-small-cell lung cancer. BMC Cancer. 2014 Apr 25; 14:290. PMID: 24766732; PMCID: PMC4017965.
    34. Varlotto JM, Decamp MM, Flickinger JC, Lake J, Recht A, Belani CP, Reed MF, Toth JW, Mackley HB, Sciamanna CN, Lipton A, Ali SM, Mahraj RP, Gilbert CR, Yao N. Would screening for lung cancer benefit 75- to 84-year-old residents of the United States? Front Oncol. 2014; 4:37. PMID: 24639950; PMCID: PMC3945517.
    35. Ji C, Zhang L, Cheng Y, Patel R, Wu H, Zhang Y, Wang M, Ji S, Belani CP, Yang JM, Ren X. Induction of autophagy contributes to crizotinib resistance in ALK-positive lung cancer. Cancer Biol Ther. 2014 May; 15(5):570-7. PMID: 24556908; PMCID: PMC4026079.
    36. Gilbert CR, Toth JW, Kaifi JT, Belani CP, Varlotto J, Reed MF. Endobronchial valve placement for spontaneous pneumothorax from stage IIIA non-small cell lung cancer facilitates neoadjuvant therapy. Ann Thorac Surg. 2013 Dec; 96(6):2225-7. PMID: 24296192.
      View in: PubMed
    37. Harouaka RA, Zhou MD, Yeh YT, Khan WJ, Das A, Liu X, Christ CC, Dicker DT, Baney TS, Kaifi JT, Belani CP, Truica CI, El-Deiry WS, Allerton JP, Zheng SY. Flexible micro spring array device for high-throughput enrichment of viable circulating tumor cells. Clin Chem. 2014 Feb; 60(2):323-33. PMID: 24132944.
      View in: PubMed
    38. Ramalingam SS, Kotsakis A, Tarhini AA, Heron DE, Smith R, Friedland D, Petro DP, Raez LE, Brahmer JR, Greenberger JS, Dacic S, Hershberger P, Landreneau RJ, Luketich JD, Belani CP, Argiris A. A multicenter phase II study of cetuximab in combination with chest radiotherapy and consolidation chemotherapy in patients with stage III non-small cell lung cancer. Lung Cancer. 2013 Sep; 81(3):416-21. PMID: 23849982.
      View in: PubMed
    39. Mauguen A, Pignon JP, Burdett S, Domerg C, Fisher D, Paulus R, Mandrekar SJ, Belani CP, Shepherd FA, Eisen T, Pang H, Collette L, Sause WT, Dahlberg SE, Crawford J, O'Brien M, Schild SE, Parmar M, Tierney JF, Le Pechoux C, Michiels S. Surrogate endpoints for overall survival in chemotherapy and radiotherapy trials in operable and locally advanced lung cancer: a re-analysis of meta-analyses of individual patients' data. Lancet Oncol. 2013 Jun; 14(7):619-26. PMID: 23680111; PMCID: PMC3732017.
    40. Belani CP, Nemunaitis JJ, Chachoua A, Eisenberg PD, Raez LE, Cuevas JD, Mather CB, Benner RJ, Meech SJ. Phase 2 trial of erlotinib with or without PF-3512676 (CPG 7909, a Toll-like receptor 9 agonist) in patients with advanced recurrent EGFR-positive non-small cell lung cancer. Cancer Biol Ther. 2013 Jul; 14(7):557-63. PMID: 23792641; PMCID: PMC3742485.
    41. Shibata SI, Chung V, Synold TW, Longmate JA, Suttle AB, Ottesen LH, Lenz HJ, Kummar S, Harvey RD, Hamilton AL, O'Neil BH, Sarantopoulos J, LoRusso P, Rudek MA, Dowlati A, Mulkerin DL, Belani CP, Gandhi L, Lau SC, Ivy SP, Newman EM. Phase I study of pazopanib in patients with advanced solid tumors and hepatic dysfunction: a National Cancer Institute Organ Dysfunction Working Group study. Clin Cancer Res. 2013 Jul 01; 19(13):3631-9. PMID: 23653147; PMCID: PMC3700623.
    42. Varlotto J, Fakiris A, Flickinger J, Medford-Davis L, Liss A, Shelkey J, Belani C, DeLuca J, Recht A, Maheshwari N, Barriger R, Yao N, DeCamp M. Matched-pair and propensity score comparisons of outcomes of patients with clinical stage I non-small cell lung cancer treated with resection or stereotactic radiosurgery. Cancer. 2013 Aug 01; 119(15):2683-91. PMID: 23605504.
      View in: PubMed
    43. Obasaju C, Bowman L, Wang P, Shen W, Winfree KB, Smyth EN, Boye ME, John W, Brodowicz T, Belani CP. Identifying the target NSCLC patient for maintenance therapy: an analysis from a placebo-controlled, phase III trial of maintenance pemetrexed (H3E-MC-JMEN). Ann Oncol. 2013 Jun; 24(6):1534-42. PMID: 23559150; PMCID: PMC3660084.
    44. Socinski MA, Goldman J, El-Hariry I, Koczywas M, Vukovic V, Horn L, Paschold E, Salgia R, West H, Sequist LV, Bonomi P, Brahmer J, Chen LC, Sandler A, Belani CP, Webb T, Harper H, Huberman M, Ramalingam S, Wong KK, Teofilovici F, Guo W, Shapiro GI. A multicenter phase II study of ganetespib monotherapy in patients with genotypically defined advanced non-small cell lung cancer. Clin Cancer Res. 2013 Jun 01; 19(11):3068-77. PMID: 23553849; PMCID: PMC3874465.
    45. Chow LQ, Jonker DI, Dy GK, Nicholas G, Fortin C, Patricia D, Adjei AA, Belani CP, Gupta A, Park JS, Zhang S, Sbar EI, Laurie SA. A phase I trial to determine the safety, pharmacokinetics, and pharmacodynamics of intercalated BMS-690514 with paclitaxel/carboplatin (PC) in advanced or metastatic solid malignancies. Cancer Chemother Pharmacol. 2013 May; 71(5):1273-85. PMID: 23468081.
      View in: PubMed
    46. Joshi M, Ayoola A, Belani CP. Small-cell lung cancer: an update on targeted therapies. Adv Exp Med Biol. 2013; 779:385-404. PMID: 23288650.
      View in: PubMed
    47. Wu H, Ramanathan RK, Zamboni BA, Strychor S, Ramalingam S, Edwards RP, Friedland DM, Stoller RG, Belani CP, Maruca LJ, Bang YJ, Zamboni WC. Mechanism-based model characterizing bidirectional interaction between PEGylated liposomal CKD-602 (S-CKD602) and monocytes in cancer patients. Int J Nanomedicine. 2012; 7:5555-64. PMID: 23112576; PMCID: PMC3480239.
    48. Besse B, Tsao LC, Chao DT, Fang Y, Soria JC, Almokadem S, Belani CP. Phase Ib safety and pharmacokinetic study of volociximab, an anti-a5ß1 integrin antibody, in combination with carboplatin and paclitaxel in advanced non-small-cell lung cancer. Ann Oncol. 2013 Jan; 24(1):90-6. PMID: 22904239.
      View in: PubMed
    49. Mauguen A, Le Péchoux C, Saunders MI, Schild SE, Turrisi AT, Baumann M, Sause WT, Ball D, Belani CP, Bonner JA, Zajusz A, Dahlberg SE, Nankivell M, Mandrekar SJ, Paulus R, Behrendt K, Koch R, Bishop JF, Dische S, Arriagada R, De Ruysscher D, Pignon JP. Hyperfractionated or accelerated radiotherapy in lung cancer: an individual patient data meta-analysis. J Clin Oncol. 2012 Aug 01; 30(22):2788-97. PMID: 22753901; PMCID: PMC4934452.
    50. Ayoola A, Barochia A, Belani K, Belani CP. Primary and acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer: an update. Cancer Invest. 2012 Jun; 30(5):433-46. PMID: 22571344.
      View in: PubMed
    51. Medford-Davis L, Decamp M, Recht A, Flickinger J, Belani CP, Varlotto J. Surgical management of early-stage non-small cell lung carcinoma and the present and future roles of adjuvant therapy: a review for the radiation oncologist. Int J Radiat Oncol Biol Phys. 2012 Dec 01; 84(5):1048-57. PMID: 22632771.
      View in: PubMed
    52. Behera M, Owonikoko TK, Chen Z, Kono SA, Khuri FR, Belani CP, Ramalingam SS. Single agent maintenance therapy for advanced stage non-small cell lung cancer: a meta-analysis. Lung Cancer. 2012 Aug; 77(2):331-8. PMID: 22546678; PMCID: PMC3396772.
    53. Aregbe AO, Sherer EA, Egorin MJ, Scher HI, Solit DB, Ramanathan RK, Ramalingam S, Belani CP, Ivy PS, Bies RR. Population pharmacokinetic analysis of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) in adult patients with solid tumors. Cancer Chemother Pharmacol. 2012 Jul; 70(1):201-5. PMID: 22450873; PMCID: PMC3383947.
    54. Joshi M, Jiang Y, Belani CP. Maintenance therapy for advanced non-small-cell lung cancer: switch versus continuation. Expert Opin Pharmacother. 2012 Apr; 13(5):685-97. PMID: 22404744.
      View in: PubMed
    55. Belani CP, Wu YL, Chen YM, Kim JH, Yang SH, Zhang L, Peterson P, Orlando M. Efficacy and safety of pemetrexed maintenance therapy versus best supportive care in patients from East Asia with advanced, nonsquamous non-small cell lung cancer: an exploratory subgroup analysis of a global, randomized, phase 3 clinical trial. J Thorac Oncol. 2012 Mar; 7(3):567-73. PMID: 22157370.
      View in: PubMed
    56. Gitlitz BJ, Tsao-Wei DD, Groshen S, Davies A, Koczywas M, Belani CP, Argiris A, Ramalingam S, Vokes EE, Edelman M, Hoffman P, Ballas MS, Liu SV, Gandara DR. A phase II study of halichondrin B analog eribulin mesylate (E7389) in patients with advanced non-small cell lung cancer previously treated with a taxane: a California cancer consortium trial. J Thorac Oncol. 2012 Mar; 7(3):574-8. PMID: 22198425; PMCID: PMC3288403.
    57. Belani CP, Brodowicz T, Ciuleanu TE, Krzakowski M, Yang SH, Franke F, Cucevic B, Madhavan J, Santoro A, Ramlau R, Liepa AM, Visseren-Grul C, Peterson P, John WJ, Zielinski CC. Quality of life in patients with advanced non-small-cell lung cancer given maintenance treatment with pemetrexed versus placebo (H3E-MC-JMEN): results from a randomised, double-blind, phase 3 study. Lancet Oncol. 2012 Mar; 13(3):292-9. PMID: 22336221.
      View in: PubMed
    58. Kummar S, Ji J, Morgan R, Lenz HJ, Puhalla SL, Belani CP, Gandara DR, Allen D, Kiesel B, Beumer JH, Newman EM, Rubinstein L, Chen A, Zhang Y, Wang L, Kinders RJ, Parchment RE, Tomaszewski JE, Doroshow JH. A phase I study of veliparib in combination with metronomic cyclophosphamide in adults with refractory solid tumors and lymphomas. Clin Cancer Res. 2012 Mar 15; 18(6):1726-34. PMID: 22307137; PMCID: PMC3306481.
    59. Wu H, Ramanathan RK, Zamboni BA, Strychor S, Ramalingam S, Edwards RP, Friedland DM, Stoller RG, Belani CP, Maruca LJ, Bang YJ, Zamboni WC. Population pharmacokinetics of pegylated liposomal CKD-602 (S-CKD602) in patients with advanced malignancies. J Clin Pharmacol. 2012 Feb; 52(2):180-94. PMID: 21233302.
      View in: PubMed
    60. Gridelli C, de Marinis F, Di Maio M, Ardizzoni A, Belani CP, Cappuzzo F, Ciardiello F, Fidias P, Paz-Ares L, Perrone F, Pirker R, De Petris L, Stahel R. Maintenance treatment of advanced non-small-cell lung cancer: results of an international expert panel meeting of the Italian association of thoracic oncology. Lung Cancer. 2012 Jun; 76(3):269-79. PMID: 22266040.
      View in: PubMed
    61. Wakelee HA, Dahlberg SE, Brahmer JR, Schiller JH, Perry MC, Langer CJ, Sandler AB, Belani CP, Johnson DH. Differential effect of age on survival in advanced NSCLC in women versus men: analysis of recent Eastern Cooperative Oncology Group (ECOG) studies, with and without bevacizumab. Lung Cancer. 2012 Jun; 76(3):410-5. PMID: 22266041; PMCID: PMC3460639.
    62. Almokadem S, Belani CP. Volociximab in cancer. Expert Opin Biol Ther. 2012 Feb; 12(2):251-7. PMID: 22192080.
      View in: PubMed
    63. Chao J, Synold TW, Morgan RJ, Kunos C, Longmate J, Lenz HJ, Lim D, Shibata S, Chung V, Stoller RG, Belani CP, Gandara DR, McNamara M, Gitlitz BJ, Lau DH, Ramalingam SS, Davies A, Espinoza-Delgado I, Newman EM, Yen Y. A phase I and pharmacokinetic study of oral 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, NSC #663249) in the treatment of advanced-stage solid cancers: a California Cancer Consortium Study. Cancer Chemother Pharmacol. 2012 Mar; 69(3):835-43. PMID: 22105720; PMCID: PMC3288125.
    64. Ramalingam SS, Davies AM, Longmate J, Edelman MJ, Lara PN, Vokes EE, Villalona-Calero M, Gitlitz B, Reckamp K, Salgia R, Wright JJ, Belani CP, Gandara DR. Bortezomib for patients with advanced-stage bronchioloalveolar carcinoma: a California Cancer Consortium Phase II study (NCI 7003). J Thorac Oncol. 2011 Oct; 6(10):1741-5. PMID: 21716143; PMCID: PMC3220078.
    65. Kaifi JT, Toth JW, Gusani NJ, Kimchi ET, Staveley-O'Carroll KF, Belani CP, Reed MF. Multidisciplinary management of malignant pleural effusion. J Surg Oncol. 2012 Jun 01; 105(7):731-8. PMID: 21960207.
      View in: PubMed
    66. O'Bryant CL, Haluska P, Rosen L, Ramanathan RK, Venugopal B, Leong S, Boinpally R, Franke A, Witt K, Evans J, Belani C, Gail Eckhardt S, Ramalingam S. An open-label study to describe pharmacokinetic parameters of erlotinib in patients with advanced solid tumors with adequate and moderately impaired hepatic function. Cancer Chemother Pharmacol. 2012 Mar; 69(3):605-12. PMID: 21938545.
      View in: PubMed
    67. Belani CP, Goss G, Blumenschein G. Recent clinical developments and rationale for combining targeted agents in non-small cell lung cancer (NSCLC). Cancer Treat Rev. 2012 May; 38(3):173-84. PMID: 21715100.
      View in: PubMed
    68. Ramalingam SS, Lee JW, Belani CP, Aisner SC, Kolesar J, Howe C, Velasco MR, Schiller JH. Cetuximab for the treatment of advanced bronchioloalveolar carcinoma (BAC): an Eastern Cooperative Oncology Group phase II study (ECOG 1504). J Clin Oncol. 2011 May 01; 29(13):1709-14. PMID: 21422434; PMCID: PMC3107763.
    69. Bortner JD, Richie JP, Das A, Liao J, Umstead TM, Stanley A, Stanley BA, Belani CP, El-Bayoumy K. Proteomic profiling of human plasma by iTRAQ reveals down-regulation of ITI-HC3 and VDBP by cigarette smoking. J Proteome Res. 2011 Mar 04; 10(3):1151-9. PMID: 21186835.
      View in: PubMed
    70. Tarhini AA, Belani CP, Luketich JD, Argiris A, Ramalingam SS, Gooding W, Pennathur A, Petro D, Kane K, Liggitt D, Championsmith T, Zhang X, Epperly MW, Greenberger JS. A phase I study of concurrent chemotherapy (paclitaxel and carboplatin) and thoracic radiotherapy with swallowed manganese superoxide dismutase plasmid liposome protection in patients with locally advanced stage III non-small-cell lung cancer. Hum Gene Ther. 2011 Mar; 22(3):336-42. PMID: 20873987; PMCID: PMC3057216.
    71. Lara PN, Longmate J, Reckamp K, Gitlitz B, Argiris A, Ramalingam S, Belani CP, Mack PC, Lau DH, Koczywas M, Wright JJ, Shepherd FA, Leighl N, Gandara DR. Randomized phase II trial of concurrent versus sequential bortezomib plus docetaxel in advanced non-small-cell lung cancer: a California cancer consortium trial. Clin Lung Cancer. 2011 Jan; 12(1):33-7. PMID: 21273177; PMCID: PMC3777729.
    72. Scagliotti G, Brodowicz T, Shepherd FA, Zielinski C, Vansteenkiste J, Manegold C, Simms L, Fossella F, Sugarman K, Belani CP. Treatment-by-histology interaction analyses in three phase III trials show superiority of pemetrexed in nonsquamous non-small cell lung cancer. J Thorac Oncol. 2011 Jan; 6(1):64-70. PMID: 21119545.
      View in: PubMed
    73. Tarhini A, Kotsakis A, Gooding W, Shuai Y, Petro D, Friedland D, Belani CP, Dacic S, Argiris A. Phase II study of everolimus (RAD001) in previously treated small cell lung cancer. Clin Cancer Res. 2010 Dec 01; 16(23):5900-7. PMID: 21045083.
      View in: PubMed
    74. Ramalingam SS, Kummar S, Sarantopoulos J, Shibata S, LoRusso P, Yerk M, Holleran J, Lin Y, Beumer JH, Harvey RD, Ivy SP, Belani CP, Egorin MJ. Phase I study of vorinostat in patients with advanced solid tumors and hepatic dysfunction: a National Cancer Institute Organ Dysfunction Working Group study. J Clin Oncol. 2010 Oct 10; 28(29):4507-12. PMID: 20837947; PMCID: PMC2988640.
    75. Heath EI, Lorusso P, Ramalingam SS, Awada A, Egorin MJ, Besse-Hamer T, Cardoso F, Valdivieso M, Has T, Alland L, Zhou X, Belani CP. A phase 1 study of BMS-275183, a novel oral analogue of paclitaxel given on a daily schedule to patients with advanced malignancies. Invest New Drugs. 2011 Dec; 29(6):1426-31. PMID: 20680660.
      View in: PubMed
    76. Ramalingam SS, Belani CP, Mack PC, Vokes EE, Longmate J, Govindan R, Koczywas M, Ivy SP, Gandara DR. Phase II study of Cediranib (AZD 2171), an inhibitor of the vascular endothelial growth factor receptor, for second-line therapy of small cell lung cancer (National Cancer Institute #7097). J Thorac Oncol. 2010 Aug; 5(8):1279-84. PMID: 20559150; PMCID: PMC2911495.
    77. Zamboni WC, Maruca LJ, Strychor S, Zamboni BA, Ramalingam S, Edwards RP, Kim J, Bang Y, Lee H, Friedland DM, Stoller RG, Belani CP, Ramanathan RK. Bidirectional pharmacodynamic interaction between pegylated liposomal CKD-602 (S-CKD602) and monocytes in patients with refractory solid tumors. J Liposome Res. 2011 Jun; 21(2):158-65. PMID: 20626314.
      View in: PubMed
    78. Jiang Y, Owonikoko TK, Ramalingam SS, Khuri FR, Belani CP. What is the role of maintenance therapy in the treatment of non-small cell lung cancer? Ther Adv Med Oncol. 2010 Jul; 2(4):229-35. PMID: 21789136; PMCID: PMC3126019.
    79. Holen KD, Belani CP, Wilding G, Ramalingam S, Volkman JL, Ramanathan RK, Vasist LS, Bowen CJ, Hodge JP, Dar MM, Ho PT. A first in human study of SB-743921, a kinesin spindle protein inhibitor, to determine pharmacokinetics, biologic effects and establish a recommended phase II dose. Cancer Chemother Pharmacol. 2011 Feb; 67(2):447-54. PMID: 20461380; PMCID: PMC4160065.
    80. Burris HA, Belani CP, Kaufman PA, Gordon AN, Schwartzberg LS, Paroly WS, Shahin S, Dreiling L, Saven A. Pegfilgrastim on the Same Day Versus Next Day of Chemotherapy in Patients With Breast Cancer, Non-Small-Cell Lung Cancer, Ovarian Cancer, and Non-Hodgkin's Lymphoma: Results of Four Multicenter, Double-Blind, Randomized Phase II Studies. J Oncol Pract. 2010 May; 6(3):133-40. PMID: 20808556; PMCID: PMC2868638.
    81. Belani CP. The role of irreversible EGFR inhibitors in the treatment of non-small cell lung cancer: overcoming resistance to reversible EGFR inhibitors. Cancer Invest. 2010 May; 28(4):413-23. PMID: 20307200.
      View in: PubMed
    82. Ansari RH, Socinski MA, Edelman MJ, Belani CP, Gonin R, Catalano RB, Marinucci DM, Comis RL, Obasaju CK, Chen R, Monberg MJ, Treat J. A retrospective analysis of outcomes by age in a three-arm phase III trial of gemcitabine in combination with carboplatin or paclitaxel vs. paclitaxel plus carboplatin for advanced non-small cell lung cancer. Crit Rev Oncol Hematol. 2011 May; 78(2):162-71. PMID: 20413322.
      View in: PubMed
    83. Owonikoko TK, Ramalingam SS, Belani CP. Maintenance therapy for advanced non-small cell lung cancer: current status, controversies, and emerging consensus. Clin Cancer Res. 2010 May 01; 16(9):2496-504. PMID: 20388843.
      View in: PubMed
    84. Treat J, Edelman MJ, Belani CP, Socinski MA, Monberg MJ, Chen R, Obasaju CK. A retrospective analysis of outcomes across histological subgroups in a three-arm phase III trial of gemcitabine in combination with carboplatin or paclitaxel versus paclitaxel plus carboplatin for advanced non-small cell lung cancer. Lung Cancer. 2010 Dec; 70(3):340-6. PMID: 20347506.
      View in: PubMed
    85. Ramalingam SS, Belani CP. Antiangiogenic agents in the treatment of nonsmall cell lung cancer: reality and hope. Curr Opin Oncol. 2010 Mar; 22(2):79-85. PMID: 20009926.
      View in: PubMed
    86. Ramalingam SS, Foster J, Gooding W, Evans T, Sulecki M, Belani CP. Phase 2 study of irinotecan and paclitaxel in patients with recurrent or refractory small cell lung cancer. Cancer. 2010 Mar 01; 116(5):1344-9. PMID: 20082454.
      View in: PubMed
    87. Ramanathan RK, Egorin MJ, Erlichman C, Remick SC, Ramalingam SS, Naret C, Holleran JL, TenEyck CJ, Ivy SP, Belani CP. Phase I pharmacokinetic and pharmacodynamic study of 17-dimethylaminoethylamino-17-demethoxygeldanamycin, an inhibitor of heat-shock protein 90, in patients with advanced solid tumors. J Clin Oncol. 2010 Mar 20; 28(9):1520-6. PMID: 20177028; PMCID: PMC2849772.
    88. Owonikoko TK, Ramalingam SS, Kanterewicz B, Balius TE, Belani CP, Hershberger PA. Vorinostat increases carboplatin and paclitaxel activity in non-small-cell lung cancer cells. Int J Cancer. 2010 Feb 01; 126(3):743-55. PMID: 19621389; PMCID: PMC2795066.
    89. Belani CP, Liao J. Maintenance therapy for non-small-cell lung cancer. Lancet. 2010 Jan 23; 375(9711):281-2. PMID: 20109952.
      View in: PubMed
    90. Edelman MJ, Belani CP, Socinski MA, Ansari RH, Obasaju CK, Chen R, Monberg MJ, Treat J. Outcomes associated with brain metastases in a three-arm phase III trial of gemcitabine-containing regimens versus paclitaxel plus carboplatin for advanced non-small cell lung cancer. J Thorac Oncol. 2010 Jan; 5(1):110-6. PMID: 20035187.
      View in: PubMed
    91. Ramalingam SS, Maitland ML, Frankel P, Argiris AE, Koczywas M, Gitlitz B, Thomas S, Espinoza-Delgado I, Vokes EE, Gandara DR, Belani CP. Carboplatin and Paclitaxel in combination with either vorinostat or placebo for first-line therapy of advanced non-small-cell lung cancer. J Clin Oncol. 2010 Jan 01; 28(1):56-62. PMID: 19933908; PMCID: PMC2799233.
    92. Morgensztern D, Belani CP. Novel cytotoxic agents. J Thorac Oncol. 2009 Nov; 4(11 Suppl 3):S1082-3. PMID: 19861926.
      View in: PubMed
    93. Treat JA, Gonin R, Socinski MA, Edelman MJ, Catalano RB, Marinucci DM, Ansari R, Gillenwater HH, Rowland KM, Comis RL, Obasaju CK, Belani CP. A randomized, phase III multicenter trial of gemcitabine in combination with carboplatin or paclitaxel versus paclitaxel plus carboplatin in patients with advanced or metastatic non-small-cell lung cancer. Ann Oncol. 2010 Mar; 21(3):540-7. PMID: 19833819.
      View in: PubMed
    94. Ciuleanu T, Brodowicz T, Zielinski C, Kim JH, Krzakowski M, Laack E, Wu YL, Bover I, Begbie S, Tzekova V, Cucevic B, Pereira JR, Yang SH, Madhavan J, Sugarman KP, Peterson P, John WJ, Krejcy K, Belani CP. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet. 2009 Oct 24; 374(9699):1432-40. PMID: 19767093.
      View in: PubMed
    95. Pallis AG, Gridelli C, van Meerbeeck JP, Greillier L, Wedding U, Lacombe D, Welch J, Belani CP, Aapro M. EORTC Elderly Task Force and Lung Cancer Group and International Society for Geriatric Oncology (SIOG) experts' opinion for the treatment of non-small-cell lung cancer in an elderly population. Ann Oncol. 2010 Apr; 21(4):692-706. PMID: 19717538.
      View in: PubMed
    96. Zamboni WC, Strychor S, Maruca L, Ramalingam S, Zamboni BA, Wu H, Friedland DM, Edwards RP, Stoller RG, Belani CP, Ramanathan RK. Pharmacokinetic study of pegylated liposomal CKD-602 (S-CKD602) in patients with advanced malignancies. Clin Pharmacol Ther. 2009 Nov; 86(5):519-26. PMID: 19675541.
      View in: PubMed
    97. Siegel D, Hussein M, Belani C, Robert F, Galanis E, Richon VM, Garcia-Vargas J, Sanz-Rodriguez C, Rizvi S. Vorinostat in solid and hematologic malignancies. J Hematol Oncol. 2009 Jul 27; 2:31. PMID: 19635146; PMCID: PMC2731787.
    98. Zamboni WC, Ramalingam S, Friedland DM, Edwards RP, Stoller RG, Strychor S, Maruca L, Zamboni BA, Belani CP, Ramanathan RK. Phase I and pharmacokinetic study of pegylated liposomal CKD-602 in patients with advanced malignancies. Clin Cancer Res. 2009 Feb 15; 15(4):1466-72. PMID: 19190127; PMCID: PMC3428134.
    99. Ramanathan RK, Belani CP, Singh DA, Tanaka M, Lenz HJ, Yen Y, Kindler HL, Iqbal S, Longmate J, Mack PC, Lurje G, Gandour-Edwards R, Dancey J, Gandara DR. A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer. Cancer Chemother Pharmacol. 2009 Sep; 64(4):777-83. PMID: 19169683.
      View in: PubMed
    100. Ramalingam SS, Belani CP, Ruel C, Frankel P, Gitlitz B, Koczywas M, Espinoza-Delgado I, Gandara D. Phase II study of belinostat (PXD101), a histone deacetylase inhibitor, for second line therapy of advanced malignant pleural mesothelioma. J Thorac Oncol. 2009 Jan; 4(1):97-101. PMID: 19096314; PMCID: PMC3263397.
    101. Belani CP, Schreeder MT, Steis RG, Guidice RA, Marsland TA, Butler EH, Ramalingam SS. Cetuximab in combination with carboplatin and docetaxel for patients with metastatic or advanced-stage nonsmall cell lung cancer: a multicenter phase 2 study. Cancer. 2008 Nov 01; 113(9):2512-7. PMID: 18816622.
      View in: PubMed
    102. Gandara DR, Lara PN, Natale R, Belani C. Progress in small-cell lung cancer: the lowest common denominator. J Clin Oncol. 2008 Sep 10; 26(26):4236-8. PMID: 18779609.
      View in: PubMed
    103. Ramalingam SS, Belani CP. Recent advances in the treatment of malignant pleural mesothelioma. J Thorac Oncol. 2008 Sep; 3(9):1056-64. PMID: 18758312.
      View in: PubMed
    104. Ramalingam S, Perry MC, La Rocca RV, Rinaldi D, Gable PS, Tester WJ, Belani CP. Comparison of outcomes for elderly patients treated with weekly paclitaxel in combination with carboplatin versus the standard 3-weekly paclitaxel and carboplatin for advanced nonsmall cell lung cancer. Cancer. 2008 Aug 01; 113(3):542-6. PMID: 18512224.
      View in: PubMed
    105. Yen Y, Lim DW, Chung V, Morgan RJ, Leong LA, Shibata SI, Wagman LD, Wagman SD, Marx H, Chu PG, Longmate JA, Lenz HJ, Ramanathan RK, Belani CP, Gandara DR. Phase II study of oxaliplatin in patients with unresectable, metastatic, or recurrent hepatocellular cancer: a California Cancer Consortium Trial. Am J Clin Oncol. 2008 Aug; 31(4):317-22. PMID: 18845988.
      View in: PubMed
    106. Ramalingam SS, Egorin MJ, Ramanathan RK, Remick SC, Sikorski RP, Lagattuta TF, Chatta GS, Friedland DM, Stoller RG, Potter DM, Ivy SP, Belani CP. A phase I study of 17-allylamino-17-demethoxygeldanamycin combined with paclitaxel in patients with advanced solid malignancies. Clin Cancer Res. 2008 Jun 01; 14(11):3456-61. PMID: 18519777.
      View in: PubMed
    107. Pennathur A, Luketich JD, Landreneau RJ, Ward J, Christie NA, Gibson MK, Schuchert M, Cooper K, Land SR, Belani CP. Long-term results of a phase II trial of neoadjuvant chemotherapy followed by esophagectomy for locally advanced esophageal neoplasm. Ann Thorac Surg. 2008 Jun; 85(6):1930-6; discussion 1936-7. PMID: 18498797.
      View in: PubMed
    108. Ramalingam S, Forster J, Naret C, Evans T, Sulecki M, Lu H, Teegarden P, Weber MR, Belani CP. Dual inhibition of the epidermal growth factor receptor with cetuximab, an IgG1 monoclonal antibody, and gefitinib, a tyrosine kinase inhibitor, in patients with refractory non-small cell lung cancer (NSCLC): a phase I study. J Thorac Oncol. 2008 Mar; 3(3):258-64. PMID: 18317068.
      View in: PubMed
    109. Ramanathan RK, Egorin MJ, Takimoto CH, Remick SC, Doroshow JH, LoRusso PA, Mulkerin DL, Grem JL, Hamilton A, Murgo AJ, Potter DM, Belani CP, Hayes MJ, Peng B, Ivy SP. Phase I and pharmacokinetic study of imatinib mesylate in patients with advanced malignancies and varying degrees of liver dysfunction: a study by the National Cancer Institute Organ Dysfunction Working Group. J Clin Oncol. 2008 Feb 01; 26(4):563-9. PMID: 18235115.
      View in: PubMed
    110. Socinski MA, Novello S, Brahmer JR, Rosell R, Sanchez JM, Belani CP, Govindan R, Atkins JN, Gillenwater HH, Pallares C, Tye L, Selaru P, Chao RC, Scagliotti GV. Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer. J Clin Oncol. 2008 Feb 01; 26(4):650-6. PMID: 18235126; PMCID: PMC3559017.
    111. Belani CP, Ramalingam S, Perry MC, LaRocca RV, Rinaldi D, Gable PS, Tester WJ. Randomized, phase III study of weekly paclitaxel in combination with carboplatin versus standard every-3-weeks administration of carboplatin and paclitaxel for patients with previously untreated advanced non-small-cell lung cancer. J Clin Oncol. 2008 Jan 20; 26(3):468-73. PMID: 18202422.
      View in: PubMed
    112. Ramalingam SS, Dahlberg SE, Langer CJ, Gray R, Belani CP, Brahmer JR, Sandler AB, Schiller JH, Johnson DH. Outcomes for elderly, advanced-stage non small-cell lung cancer patients treated with bevacizumab in combination with carboplatin and paclitaxel: analysis of Eastern Cooperative Oncology Group Trial 4599. J Clin Oncol. 2008 Jan 01; 26(1):60-5. PMID: 18165641.
      View in: PubMed
    113. Ramalingam S, Belani C. Systemic chemotherapy for advanced non-small cell lung cancer: recent advances and future directions. Oncologist. 2008; 13 Suppl 1:5-13. PMID: 18263769.
      View in: PubMed
    114. Owonikoko TK, Ragin CC, Belani CP, Oton AB, Gooding WE, Taioli E, Ramalingam SS. Lung cancer in elderly patients: an analysis of the surveillance, epidemiology, and end results database. J Clin Oncol. 2007 Dec 10; 25(35):5570-7. PMID: 18065729.
      View in: PubMed
    115. Feng R, Oton A, Mapara MY, Anderson G, Belani C, Lentzsch S. The histone deacetylase inhibitor, PXD101, potentiates bortezomib-induced anti-multiple myeloma effect by induction of oxidative stress and DNA damage. Br J Haematol. 2007 Nov; 139(3):385-97. PMID: 17910628.
      View in: PubMed
    116. Herbst RS, O'Neill VJ, Fehrenbacher L, Belani CP, Bonomi PD, Hart L, Melnyk O, Ramies D, Lin M, Sandler A. Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer. J Clin Oncol. 2007 Oct 20; 25(30):4743-50. PMID: 17909199.
      View in: PubMed
    117. Heymach JV, Johnson BE, Prager D, Csada E, Roubec J, Pesek M, Spásová I, Belani CP, Bodrogi I, Gadgeel S, Kennedy SJ, Hou J, Herbst RS. Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non small-cell lung cancer. J Clin Oncol. 2007 Sep 20; 25(27):4270-7. PMID: 17878479.
      View in: PubMed
    118. Charu V, Belani CP, Gill AN, Bhatt M, Tomita D, Rossi G, Ben-Jacob A. Efficacy and safety of every-2-week darbepoetin alfa in patients with anemia of cancer: a controlled, randomized, open-label phase II trial. Oncologist. 2007 Jun; 12(6):727-37. PMID: 17602062.
      View in: PubMed
    119. Ramalingam SS, Parise RA, Ramanathan RK, Ramananthan RK, Lagattuta TF, Musguire LA, Stoller RG, Potter DM, Argiris AE, Zwiebel JA, Egorin MJ, Belani CP. Phase I and pharmacokinetic study of vorinostat, a histone deacetylase inhibitor, in combination with carboplatin and paclitaxel for advanced solid malignancies. Clin Cancer Res. 2007 Jun 15; 13(12):3605-10. PMID: 17510206.
      View in: PubMed
    120. Ramalingam S, Belani CP. Role of bevacizumab for the treatment of non-small-cell lung cancer. Future Oncol. 2007 Apr; 3(2):131-9. PMID: 17381412.
      View in: PubMed
    121. Ramanathan RK, Kirkpatrick DL, Belani CP, Friedland D, Green SB, Chow HH, Cordova CA, Stratton SP, Sharlow ER, Baker A, Dragovich T. A Phase I pharmacokinetic and pharmacodynamic study of PX-12, a novel inhibitor of thioredoxin-1, in patients with advanced solid tumors. Clin Cancer Res. 2007 Apr 01; 13(7):2109-14. PMID: 17404093.
      View in: PubMed
    122. Eiseman JL, Guo J, Ramanathan RK, Belani CP, Solit DB, Scher HI, Ivy SP, Zuhowski EG, Egorin MJ. Evaluation of plasma insulin-like growth factor binding protein 2 and Her-2 extracellular domain as biomarkers for 17-allylamino-17-demethoxygeldanamycin treatment of adult patients with advanced solid tumors. Clin Cancer Res. 2007 Apr 01; 13(7):2121-7. PMID: 17404095.
      View in: PubMed
    123. Ramanathan RK, Egorin MJ, Eiseman JL, Ramalingam S, Friedland D, Agarwala SS, Ivy SP, Potter DM, Chatta G, Zuhowski EG, Stoller RG, Naret C, Guo J, Belani CP. Phase I and pharmacodynamic study of 17-(allylamino)-17-demethoxygeldanamycin in adult patients with refractory advanced cancers. Clin Cancer Res. 2007 Mar 15; 13(6):1769-74. PMID: 17363531.
      View in: PubMed
    124. Crawford J, Robert F, Perry MC, Belani C, Williams D. A randomized trial comparing immediate versus delayed treatment of anemia with once-weekly epoetin alfa in patients with non-small cell lung cancer scheduled to receive first-line chemotherapy. J Thorac Oncol. 2007 Mar; 2(3):210-20. PMID: 17410044.
      View in: PubMed
    125. Ramalingam S, Belani CP. Recent advances in targeted therapy for non-small cell lung cancer. Expert Opin Ther Targets. 2007 Feb; 11(2):245-57. PMID: 17227238.
      View in: PubMed
    126. Gerszten PC, Burton SA, Belani CP, Ramalingam S, Friedland DM, Ozhasoglu C, Quinn AE, McCue KJ, Welch WC. Radiosurgery for the treatment of spinal lung metastases. Cancer. 2006 Dec 01; 107(11):2653-61. PMID: 17063501.
      View in: PubMed
    127. Obasaju CK, Ye Z, Wozniak AJ, Belani CP, Keohan ML, Ross HJ, Polikoff JA, Mintzer DM, Monberg MJ, Jänne PA. Single-arm, open label study of pemetrexed plus cisplatin in chemotherapy naïve patients with malignant pleural mesothelioma: outcomes of an expanded access program. Lung Cancer. 2007 Feb; 55(2):187-94. PMID: 17092602.
      View in: PubMed
    128. Belani CP, Marts S, Schiller J, Socinski MA. Women and lung cancer: epidemiology, tumor biology, and emerging trends in clinical research. Lung Cancer. 2007 Jan; 55(1):15-23. PMID: 17084482.
      View in: PubMed
    129. Belani CP, Dakhil S, Waterhouse DM, Desch CE, Rooney DK, Clark RH, Monberg MJ, Ye Z, Obasaju CK. Randomized phase II trial of gemcitabine plus weekly versus three-weekly paclitaxel in previously untreated advanced non-small-cell lung cancer. Ann Oncol. 2007 Jan; 18(1):110-5. PMID: 17043094.
      View in: PubMed
    130. Jänne PA, Wozniak AJ, Belani CP, Keohan ML, Ross HJ, Polikoff JA, Mintzer DM, Ye Z, Monberg MJ, Obasaju CK. Pemetrexed alone or in combination with cisplatin in previously treated malignant pleural mesothelioma: outcomes from a phase IIIB expanded access program. J Thorac Oncol. 2006 Jul; 1(6):506-12. PMID: 17409909.
      View in: PubMed
    131. Govindan R, Natale R, Wade J, Herbst R, Krebs A, Reiling R, Hensing T, Wozniak A, Belani CP, Kelly K, Ochs J. Efficacy and safety of gefitinib in chemonaive patients with advanced non-small cell lung cancer treated in an Expanded Access Program. Lung Cancer. 2006 Sep; 53(3):331-7. PMID: 16797779.
      View in: PubMed
    132. Belani CP, Pereira JR, von Pawel J, Pluzanska A, Gorbounova V, Kaukel E, Mattson KV, Ramlau R, Szczesna A, Fidias P, Millward M, Fossella F. Effect of chemotherapy for advanced non-small cell lung cancer on patients' quality of life. A randomized controlled trial. Lung Cancer. 2006 Aug; 53(2):231-9. PMID: 16787687.
      View in: PubMed
    133. Dacic S, Flanagan M, Cieply K, Ramalingam S, Luketich J, Belani C, Yousem SA. Significance of EGFR protein expression and gene amplification in non-small cell lung carcinoma. Am J Clin Pathol. 2006 Jun; 125(6):860-5. PMID: 16690485.
      View in: PubMed
    134. Wakelee HA, Wang W, Schiller JH, Langer CJ, Sandler AB, Belani CP, Johnson DH. Survival differences by sex for patients with advanced non-small cell lung cancer on Eastern Cooperative Oncology Group trial 1594. J Thorac Oncol. 2006 Jun; 1(5):441-6. PMID: 17409897.
      View in: PubMed
    135. Albain KS, Belani CP, Bonomi P, O'Byrne KJ, Schiller JH, Socinski M. PIONEER: a phase III randomized trial of paclitaxel poliglumex versus paclitaxel in chemotherapy-naive women with advanced-stage non-small-cell lung cancer and performance status of 2. Clin Lung Cancer. 2006 May; 7(6):417-9. PMID: 16800969.
      View in: PubMed
    136. Ramalingam S, Barstis J, Perry MC, La Rocca RV, Nattam SR, Rinaldi D, Clark R, Mills GM, Belani CP. Treatment of elderly non-small cell lung cancer patients with three different schedules of weekly paclitaxel in combination with carboplatin: subanalysis of a randomized trial. J Thorac Oncol. 2006 Mar; 1(3):240-4. PMID: 17409863.
      View in: PubMed
    137. Belani CP, Fossella F. Elderly subgroup analysis of a randomized phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for first-line treatment of advanced nonsmall cell lung carcinoma (TAX 326). Cancer. 2005 Dec 15; 104(12):2766-74. PMID: 16288485.
      View in: PubMed
    138. Ramalingam S, Belani CP. Molecularly-targeted therapies for non-small cell lung cancer. Expert Opin Pharmacother. 2005 Dec; 6(15):2667-79. PMID: 16316305.
      View in: PubMed
    139. Belani CP. Optimizing chemotherapy for advanced non-small cell lung cancer: focus on docetaxel. Lung Cancer. 2005 Dec; 50 Suppl 2:S3-8. PMID: 16557668.
      View in: PubMed
    140. Belani CP. Optimizing chemotherapy for advanced non-small cell lung cancer: focus on docetaxel. Lung Cancer. 2005 Dec; 50S2:S3-S8. PMID: 16551520.
      View in: PubMed
    141. Wolski MJ, Bhatnagar A, Flickinger JC, Belani CP, Ramalingam S, Greenberger JS. Multivariate analysis of survival, local control, and time to distant metastases in patients with unresectable non-small-cell lung carcinoma treated with 3-dimensional conformal radiation therapy with or without concurrent chemotherapy. Clin Lung Cancer. 2005 Sep; 7(2):100-6. PMID: 16179096.
      View in: PubMed
    142. Ramanathan RK, Fakih M, Mani S, Deutsch M, Perez RP, Ritter MA, Eiseman JL, Ivy SP, Trump DL, Belani CP, Parise RA, Potter DM, Egorin MJ. Phase I and pharmacokinetic study of the novel redox-active agent, motexafin gadolinium, with concurrent radiation therapy in patients with locally advanced pancreatic or biliary cancers. Cancer Chemother Pharmacol. 2006 Apr; 57(4):465-74. PMID: 16133531.
      View in: PubMed
    143. Belani CP, Choy H, Bonomi P, Scott C, Travis P, Haluschak J, Curran WJ. Combined chemoradiotherapy regimens of paclitaxel and carboplatin for locally advanced non-small-cell lung cancer: a randomized phase II locally advanced multi-modality protocol. J Clin Oncol. 2005 Sep 01; 23(25):5883-91. PMID: 16087941.
      View in: PubMed
    144. Belani CP, Ramalingam S. Molecular predictors of sensitivity to epidermal growth factor receptor tyrosine kinase inhibitor: confusion or clarity? Clin Lung Cancer. 2005 Jul; 7(1):8. PMID: 16098237.
      View in: PubMed
    145. Jänne PA, Wozniak AJ, Belani CP, Keohan ML, Ross HJ, Polikoff JA, Mintzer DM, Taylor L, Ashland J, Ye Z, Monberg MJ, Obasaju CK. Open-label study of pemetrexed alone or in combination with cisplatin for the treatment of patients with peritoneal mesothelioma: outcomes of an expanded access program. Clin Lung Cancer. 2005 Jul; 7(1):40-6. PMID: 16098243.
      View in: PubMed
    146. Ramanathan RK, Trump DL, Eiseman JL, Belani CP, Agarwala SS, Zuhowski EG, Lan J, Potter DM, Ivy SP, Ramalingam S, Brufsky AM, Wong MK, Tutchko S, Egorin MJ. Phase I pharmacokinetic-pharmacodynamic study of 17-(allylamino)-17-demethoxygeldanamycin (17AAG, NSC 330507), a novel inhibitor of heat shock protein 90, in patients with refractory advanced cancers. Clin Cancer Res. 2005 May 01; 11(9):3385-91. PMID: 15867239.
      View in: PubMed
    147. Belani CP. The ANITA trial seals the deal for adjuvant therapy in non-small-cell lung cancer. Clin Lung Cancer. 2005 May; 6(6):331-2. PMID: 15943890.
      View in: PubMed
    148. Belani CP, Lee JS, Socinski MA, Robert F, Waterhouse D, Rowland K, Ansari R, Lilenbaum R, Natale RB. Randomized phase III trial comparing cisplatin-etoposide to carboplatin-paclitaxel in advanced or metastatic non-small cell lung cancer. Ann Oncol. 2005 Jul; 16(7):1069-75. PMID: 15860487.
      View in: PubMed
    149. Belani CP, Wang W, Johnson DH, Wagner H, Schiller J, Veeder M, Mehta M. Phase III study of the Eastern Cooperative Oncology Group (ECOG 2597): induction chemotherapy followed by either standard thoracic radiotherapy or hyperfractionated accelerated radiotherapy for patients with unresectable stage IIIA and B non-small-cell lung cancer. J Clin Oncol. 2005 Jun 01; 23(16):3760-7. PMID: 15837967.
      View in: PubMed
    150. Belani CP. Adjuvant and neoadjuvant therapy in non-small cell lung cancer. Semin Oncol. 2005 Apr; 32(2 Suppl 2):S9-15. PMID: 15818538.
      View in: PubMed
    151. Fernando HC, De Hoyos A, Landreneau RJ, Gilbert S, Gooding WE, Buenaventura PO, Christie NA, Belani C, Luketich JD. Radiofrequency ablation for the treatment of non-small cell lung cancer in marginal surgical candidates. J Thorac Cardiovasc Surg. 2005 Mar; 129(3):639-44. PMID: 15746749.
      View in: PubMed
    152. Belani CP, Ramalingam S. Bevacizumab extends survival for patients with nonsquamous non-small-cell lung cancer. Clin Lung Cancer. 2005 Mar; 6(5):267-8. PMID: 15845175.
      View in: PubMed
    153. Mohamed MK, Ramalingam S, Lin Y, Gooding W, Belani CP. Skin rash and good performance status predict improved survival with gefitinib in patients with advanced non-small cell lung cancer. Ann Oncol. 2005 May; 16(5):780-5. PMID: 15728108.
      View in: PubMed
    154. Cella D, Herbst RS, Lynch TJ, Prager D, Belani CP, Schiller JH, Heyes A, Ochs JS, Wolf MK, Kay AC, Kris MG, Natale RB. Clinically meaningful improvement in symptoms and quality of life for patients with non-small-cell lung cancer receiving gefitinib in a randomized controlled trial. J Clin Oncol. 2005 May 01; 23(13):2946-54. PMID: 15699477.
      View in: PubMed
    155. Wakelee H, Ramalingam S, Belani CP. Docetaxel in advanced non-small cell lung cancer. Expert Rev Anticancer Ther. 2005 Feb; 5(1):13-24. PMID: 15757434.
      View in: PubMed
    156. Price N, Belani C. Clinical development of gefitinib in non-small-cell lung cancer and the Iressa Survival Evaluation in Lung Cancer trial. Clin Lung Cancer. 2005 Jan; 6(4):214-6. PMID: 15694012.
      View in: PubMed
    157. Belani CP, Ramalingam S. Implications of the Iressa Survival Evaluation in Lung Cancer trial and the future of gefitinib. Clin Lung Cancer. 2005 Jan; 6(4):203-4. PMID: 15694010.
      View in: PubMed
    158. Wakelee H, Belani CP. Optimizing first-line treatment options for patients with advanced NSCLC. Oncologist. 2005; 10 Suppl 3:1-10. PMID: 16368866.
      View in: PubMed
    159. Belani CP. Integration of docetaxel in the management of non-small-cell lung cancer. Lung Cancer. 2004 Dec; 46 Suppl 2:S1-2. PMID: 15698526.
      View in: PubMed
    160. Belani CP. Emerging advances in the management of lung cancer. Clin Lung Cancer. 2004 Dec; 6 Suppl 2:S60. PMID: 15638961.
      View in: PubMed
    161. Belani CP. Emerging role of erlotinib (OSI-774) in non-small-cell lung cancer. Clin Lung Cancer. 2004 Dec; 6 Suppl 1:S6. PMID: 15638958.
      View in: PubMed
    162. Belani CP, Eckardt J. Development of docetaxel in advanced non-small-cell lung cancer. Lung Cancer. 2004 Dec; 46 Suppl 2:S3-11. PMID: 15698529.
      View in: PubMed
    163. Belani CP. Recent updates in the clinical use of platinum compounds for the treatment of lung, breast, and genitourinary tumors and myeloma. Semin Oncol. 2004 Dec; 31(6 Suppl 14):25-33. PMID: 15726531.
      View in: PubMed
    164. Belani CP, Adjei A. Combining targeted agents in lung cancer. Clin Lung Cancer. 2004 Nov; 6(3):138. PMID: 15555212.
      View in: PubMed
    165. Fernando HC, Hoyos AD, Litle V, Belani CP, Luketich JD. Radiofrequency ablation: identification of the ideal patient. Clin Lung Cancer. 2004 Nov; 6(3):149-53. PMID: 15555215.
      View in: PubMed
    166. Ramanathan RK, Ramalingam S, Egorin MJ, Belani CP, Potter DM, Fakih M, Jung LL, Strychor S, Jacobs SA, Friedland DM, Shin DM, Chatta GS, Tutchko S, Zamboni WC. Phase I study of weekly (day 1 and 8) docetaxel in combination with capecitabine in patients with advanced solid malignancies. Cancer Chemother Pharmacol. 2005 Apr; 55(4):354-360. PMID: 15723261.
      View in: PubMed
    167. Weinberg R, Kaurin DG, Choy H, Curran WJ, MacRae R, Kim JS, Kim J, Tucker SL, Bonomi PD, Belani C, Starkschall G. Dosimetric uncertainties of three-dimensional dose reconstruction from two-dimensional data in a multi-institutional study. J Appl Clin Med Phys. 2004; 5(4):15-28. PMID: 15738918.
      View in: PubMed
    168. Belani CP. Challenges in advanced NSCLC: optimizing platinum-based chemotherapy and treating special populations. J Natl Compr Canc Netw. 2004 Sep; 2 Suppl 2:S10-22. PMID: 19780242.
      View in: PubMed
    169. Ramalingam S, Belani CP. Paclitaxel for non-small cell lung cancer. Expert Opin Pharmacother. 2004 Aug; 5(8):1771-80. PMID: 15264992.
      View in: PubMed
    170. Zamboni WC, Jung LL, Egorin MJ, Potter DM, Friedland DM, Belani CP, Agarwala SS, Wong MM, Fakih M, Trump DL, Jin R, Strychor S, Vozniak M, Troetschel M, Ramanathan RK. Phase I and pharmacologic study of intermittently administered 9-nitrocamptothecin in patients with advanced solid tumors. Clin Cancer Res. 2004 Aug 01; 10(15):5058-64. PMID: 15297407.
      View in: PubMed
    171. Belani CP, Adak S, Aisner S, Stella PJ, Levitan N, Johnson DH. Docetaxel for malignant mesothelioma: phase II study of the Eastern Cooperative Oncology Group. Clin Lung Cancer. 2004 Jul; 6(1):43-7. PMID: 15310416.
      View in: PubMed
    172. Belani CP. Neoadjuvant versus adjuvant therapy for resectable non-small-cell lung cancer. Clin Lung Cancer. 2004 Jul; 6(1):8. PMID: 15310410.
      View in: PubMed
    173. Ramalingam S, Belani CP. Carboplatin/gemcitabine combination in advanced NSCLC. Oncology (Williston Park). 2004 Jul; 18(8 Suppl 5):21-6. PMID: 15339055.
      View in: PubMed
    174. Belani CP. Epidermal growth factor receptor mutations: a new insight. Clin Lung Cancer. 2004 May; 5(6):328. PMID: 15217529.
      View in: PubMed
    175. Ramalingam S, Dobbs TW, Einzig AI, Wojtowicz-Praga S, Cascino M, Bonomi P, Belani CP. Carboplatin and docetaxel in advanced non-small-cell lung cancer: results of a multicenter phase II study. Cancer Chemother Pharmacol. 2004 May; 53(5):439-44. PMID: 15132135.
      View in: PubMed
    176. Ramalingam S, Belani CP. State-of-the-art chemotherapy for advanced non-small cell lung cancer. Semin Oncol. 2004 Feb; 31(1 Suppl 1):68-74. PMID: 14981583.
      View in: PubMed
    177. Ramalingam S, Belani CP, Day R, Zamboni BA, Jacobs SA, Jett JR. Phase II study of topotecan and paclitaxel for patients with previously untreated extensive stage small-cell lung cancer. Ann Oncol. 2004 Feb; 15(2):247-51. PMID: 14760117.
      View in: PubMed
    178. Ramalingam S, Belani CP. Basic treatment considerations: chemotherapy. Hematol Oncol Clin North Am. 2004 Feb; 18(1):13-28. PMID: 15005278.
      View in: PubMed
    179. Belani CP, Ramalingam S. Lung cancer: looking ahead in 2004. Clin Lung Cancer. 2004 Jan; 5(4):200. PMID: 14967070.
      View in: PubMed
    180. Ramalingam S, Belani CP. Cyclooxygenase-2 inhibitors in lung cancer. Clin Lung Cancer. 2004 Jan; 5(4):245-53. PMID: 14967078.
      View in: PubMed
    181. Kris MG, Natale RB, Herbst RS, Lynch TJ, Prager D, Belani CP, Schiller JH, Kelly K, Spiridonidis H, Sandler A, Albain KS, Cella D, Wolf MK, Averbuch SD, Ochs JJ, Kay AC. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA. 2003 Oct 22; 290(16):2149-58. PMID: 14570950.
      View in: PubMed
    182. Ramalingam S, Belani CP. Results of clinical trials for locally advanced and metastatic nonsmall-cell lung cancer. Semin Thorac Cardiovasc Surg. 2003 Oct; 15(4):438-47. PMID: 14710386.
      View in: PubMed
    183. Belani CP. Elderly patients with advanced non-small-cell lung cancer. Clin Lung Cancer. 2003 Sep; 5(2):76. PMID: 14596687.
      View in: PubMed
    184. Bunn PA, Shepherd FA, Sandler A, Le Chevalier T, Belani CP, Kosmidis PA, Scagliotti GV, Giaccone G. Ongoing and future trials of biologic therapies in lung cancer. Lung Cancer. 2003 Aug; 41 Suppl 1:S175-86. PMID: 12867076.
      View in: PubMed
    185. Belani CP, Barstis J, Perry MC, La Rocca RV, Nattam SR, Rinaldi D, Clark R, Mills GM. Multicenter, randomized trial for stage IIIB or IV non-small-cell lung cancer using weekly paclitaxel and carboplatin followed by maintenance weekly paclitaxel or observation. J Clin Oncol. 2003 Aug 01; 21(15):2933-9. PMID: 12885812.
      View in: PubMed
    186. Belani CP. Early-stage non-small-cell lung cancer: adjuvant versus neoadjuvant chemotherapy. Clin Lung Cancer. 2003 Jul; 5(1):11-2. PMID: 14596696.
      View in: PubMed
    187. Fossella F, Pereira JR, von Pawel J, Pluzanska A, Gorbounova V, Kaukel E, Mattson KV, Ramlau R, Szczesna A, Fidias P, Millward M, Belani CP. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. J Clin Oncol. 2003 Aug 15; 21(16):3016-24. PMID: 12837811.
      View in: PubMed
    188. Belani CP. Gefitinib for non-small cell lung cancer: is the efficacy real? Clin Lung Cancer. 2003 May; 4(6):330. PMID: 14599297.
      View in: PubMed
    189. Belani CP. Adjuvant therapy for surgically resected non-small-cell lung cancer: will it become a reality? Clin Lung Cancer. 2003 Jan; 4(4):203-4. PMID: 14624705.
      View in: PubMed
    190. Belani CP. Newer cytotoxic and targeted agents are advancing the treatment of lung cancer. Clin Lung Cancer. 2003 Jan; 4 Suppl 2:S39. PMID: 14720335.
      View in: PubMed
    191. Belani CP, Langer C. First-line chemotherapy for NSCLC: an overview of relevant trials. Lung Cancer. 2002 Dec; 38 Suppl 4:13-9. PMID: 12480190.
      View in: PubMed
    192. Ramalingam S, Belani CP. Taxanes for advanced non-small cell lung cancer. Expert Opin Pharmacother. 2002 Dec; 3(12):1693-709. PMID: 12472367.
      View in: PubMed
    193. Ramanathan RK, Potter DM, Belani CP, Jacobs SA, Gravenstein S, Lim F, Kim H, Savona S, Evans T, Buchbarker D, Simon MB, Depee JK, Trump DL. Randomized trial of influenza vaccine with granulocyte-macrophage colony-stimulating factor or placebo in cancer patients. J Clin Oncol. 2002 Nov 01; 20(21):4313-8. PMID: 12409329.
      View in: PubMed
    194. Ramalingam S, Belani CP. Doublet chemotherapy for advanced non-small cell lung cancer. Clin Lung Cancer. 2002 Jul; 4(1):13. PMID: 14653870.
      View in: PubMed
    195. Belani CP. Docetaxel in combination with platinums (cisplatin or carboplatin) in advanced and metastatic non-small cell lung cancer. Semin Oncol. 2002 Jun; 29(3 Suppl 12):4-9. PMID: 12170445.
      View in: PubMed
    196. Belani CP, Sauder RJ. Docetaxel/platinum in advanced non-small-cell lung cancer: recent randomized trials. Clin Lung Cancer. 2002 May; 3 Suppl 2:S7-11. PMID: 14720341.
      View in: PubMed
    197. Bhatnagar A, Flickinger JC, Bahri S, Deutsch M, Belani C, Luketich JD, Greenberger JS. Update on results of multifield conformal radiation therapy of non-small-cell lung cancer using multileaf collimated beams. Clin Lung Cancer. 2002 May; 3(4):259-64. PMID: 14662034.
      View in: PubMed
    198. Belani CP. Chemotherapy regimens in advanced non-small-cell lung cancer: recent randomized trials. Clin Lung Cancer. 2002 Mar; 3 Suppl 1:S5-9. PMID: 14720348.
      View in: PubMed
    199. Belani CP. Extensive-stage small-cell lung cancer: is the progress real? Clin Lung Cancer. 2002 Feb; 3(3):168. PMID: 14662038.
      View in: PubMed
    200. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, Zhu J, Johnson DH. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 2002 Jan 10; 346(2):92-8. PMID: 11784875.
      View in: PubMed
    201. Sweeney CJ, Zhu J, Sandler AB, Schiller J, Belani CP, Langer C, Krook J, Harrington D, Johnson DH. Outcome of patients with a performance status of 2 in Eastern Cooperative Oncology Group Study E1594: a Phase II trial in patients with metastatic nonsmall cell lung carcinoma . Cancer. 2001 Nov 15; 92(10):2639-47. PMID: 11745199.
      View in: PubMed
    202. Belani CP. Individualized therapy for non-small cell lung cancer. Clin Lung Cancer. 2001 Aug; 3(1):11. PMID: 14656382.
      View in: PubMed
    203. Belani CP. Interim analysis of a phase II study of induction weekly paclitaxel/carboplatin regimens followed by maintenance weekly paclitaxel for advanced and metastatic non-small cell lung cancer. Semin Oncol. 2001 Aug; 28(4 Suppl 14):14-6. PMID: 11605178.
      View in: PubMed
    204. Belani C. Phase III randomized trial of docetaxel in combination with cisplatin or carboplatin or vinorelbine plus cisplatin in advanced non--small cell lung cancer: interim analysis. Semin Oncol. 2001 Jun; 28(3 Suppl 9):10-4. PMID: 11441409.
      View in: PubMed
    205. Shihabi S, Belani CP. Role of topoisomerase I inhibitors in small-cell lung cancer. Clin Lung Cancer. 2001 May; 2(4):275-81. PMID: 14720360.
      View in: PubMed
    206. Belani CP. Targets...targets...targets... Targeted therapies in lung cancer. Clin Lung Cancer. 2001 May; 2(4):251. PMID: 14720354.
      View in: PubMed
    207. Belani C, Lynch T. Docetaxel (Taxotere) in combination with platinums in patients with non-small cell lung cancer: trial data and implications for clinical management. Semin Oncol. 2001 Feb; 28(1 Suppl 2):10-4. PMID: 11284619.
      View in: PubMed
    208. Luketich JD, Friedman DM, Meltzer CC, Belani CP, Townsend DW, Christie NA, Weigel TL. The role of positron emission tomography in evaluating mediastinal lymph node metastases in non-small-cell lung cancer. Clin Lung Cancer. 2001 Feb; 2(3):229-33. PMID: 14700483.
      View in: PubMed
    209. Belani C, Lynch T. Docetaxel (Taxotere) in combination with platinums in patients with non-small cell lung cancer: Trial data and implications for clinical management. Semin Oncol. 2001 Feb; 28 Suppl 2:10-14. PMID: 28140076.
      View in: PubMed
    210. Calvo AR, Belani CP. Lung cancer: therapeutic options for stage IV and recurrent NSCLC. Cancer Treat Res. 2001; 105:189-227. PMID: 11224988.
      View in: PubMed
    211. Belani CP. Chemotherapy regimens in advanced non small-cell lung cancer: recent randomized trials. Clin Lung Cancer. 2000 Dec; 2 Suppl 1:S7-S10. PMID: 14725729.
      View in: PubMed
    212. Belani CP. Locally advanced, unresectable non-small cell lung cancer shift in the treatment paradigm. Clin Lung Cancer. 2000 Nov; 2(2):90. PMID: 14731317.
      View in: PubMed
    213. Luketich JD, Meehan MA, Landreneau RJ, Christie NA, Close JM, Ferson PF, Keenan RJ, Belani CP. Total videothoracoscopic lobectomy versus open thoracotomy for early-stage non small-cell lung cancer. Clin Lung Cancer. 2000 Aug; 2(1):56-60; discussion 61. PMID: 14731340.
      View in: PubMed
    214. Belani CP. Non-small-cell lung cancer have we reached a "chemotherapy efficacy plateau"? Clin Lung Cancer. 2000 Aug; 2(1):10. PMID: 14731330.
      View in: PubMed
    215. Belani CP, Einzig A, Bonomi P, Dobbs T, Capozzoli MJ, Earhart R, Cohen LJ, Luketich JD. Multicenter phase II trial of docetaxel and carboplatin in patients with stage IIIB and IV non-small-cell lung cancer. Ann Oncol. 2000 Jun; 11(6):673-8. PMID: 10942054.
      View in: PubMed
    216. Greenberger JS, Epperly M, Luketich J, Gooding W, Belani CP. Manganese superoxide dismutase-plasmid/liposome (MnSOD-PL) gene therapy protection of the esophagus from chemoradiotherapy damage during treatment of locally unresectable non-small-cell lung cancer (NSCLC). Clin Lung Cancer. 2000 May; 1(4):302-4. PMID: 14733636.
      View in: PubMed
    217. Belani CP. Paclitaxel and docetaxel combinations in non-small cell lung cancer. Chest. 2000 Apr; 117(4 Suppl 1):144S-151S. PMID: 10777470.
      View in: PubMed
    218. Belani CP. Combined modality therapy for unresectable stage III non-small cell lung cancer: new chemotherapy combinations. Chest. 2000 Apr; 117(4 Suppl 1):127S-132S. PMID: 10777467.
      View in: PubMed
    219. Ramanathan RK, Rubin JT, Ohori NP, Belani CP. Dramatic response of adult wilms tumor to paclitaxel and cisplatin. Med Pediatr Oncol. 2000 Apr; 34(4):296-8. PMID: 10742077.
      View in: PubMed
    220. Belani CP. Docetaxel in combination with platinum compounds for non small-cell lung cancer. Clin Lung Cancer. 2000 Apr; 1 Suppl 1:S10-4. PMID: 14725736.
      View in: PubMed
    221. Gandara DR, Vokes E, Green M, Bonomi P, Devore R, Comis R, Carbone D, Karp D, Belani C. Activity of docetaxel in platinum-treated non-small-cell lung cancer: results of a phase II multicenter trial. J Clin Oncol. 2000 Jan; 18(1):131-5. PMID: 10623703.
      View in: PubMed
    222. Kindler HL, Belani CP, Herndon JE, Vogelzang NJ, Suzuki Y, Green MR. Edatrexate (10-ethyl-deaza-aminopterin) (NSC #626715) with or without leucovorin rescue for malignant mesothelioma. Sequential phase II trials by the cancer and leukemia group B. Cancer. 1999 Nov 15; 86(10):1985-91. PMID: 10570422.
      View in: PubMed
    223. Fossella F, Rigas JR, Belani CP. New options in the treatment of non-small cell lung cancer. Anticancer Drugs. 1999 Nov; 10 Suppl 1:S25-8. PMID: 10630365.
      View in: PubMed
    224. Belani CP, Bonomi P, Dobbs TW, DeVore RF, Ettinger DS, Jett J, Luketich JD, Cohen LJ, Johnson DH. Docetaxel and cisplatin in patients with advanced non small-cell lung cancer (NSCLC): a multicenter phase II trial. Clin Lung Cancer. 1999 Nov; 1(2):144-50. PMID: 14733666.
      View in: PubMed
    225. Belani CP. Docetaxel (Taxotere) in combination with platinum-based regimens in non-small cell lung cancer: results and future developments. Semin Oncol. 1999 Jun; 26(3 Suppl 10):15-8. PMID: 10437746.
      View in: PubMed
    226. Selvaggi G, Belani CP. Carboplatin and paclitaxel in non-small cell lung cancer: the role of amifostine. Semin Oncol. 1999 Apr; 26(2 Suppl 7):51-60. PMID: 10348261.
      View in: PubMed
    227. Belani CP, Kearns CM, Zuhowski EG, Erkmen K, Hiponia D, Zacharski D, Engstrom C, Ramanathan RK, Capozzoli MJ, Aisner J, Egorin MJ. Phase I trial, including pharmacokinetic and pharmacodynamic correlations, of combination paclitaxel and carboplatin in patients with metastatic non-small-cell lung cancer. J Clin Oncol. 1999 Feb; 17(2):676-84. PMID: 10080614.
      View in: PubMed
    228. Belani CP. Incorporation of paclitaxel and carboplatin in combined-modality therapy for locally advanced non-small cell lung cancer. Semin Oncol. 1999 Feb; 26(1 Suppl 2):44-54. PMID: 10190783.
      View in: PubMed
    229. Bahri S, Flickinger JC, Kalend AM, Deutsch M, Belani CP, Sciurba FC, Luketich JD, Greenberger JS. Results of multifield conformal radiation therapy of nonsmall-cell lung carcinoma using multileaf collimation beams. Radiat Oncol Investig. 1999; 7(5):297-308. PMID: 10580899.
      View in: PubMed
    230. Treat J, Johnson E, Langer C, Belani C, Haynes B, Greenberg R, Rodriquez R, Drobins P, Miller W, Meehan L, McKeon A, Devin J, von Roemeling R, Viallet J. Tirapazamine with cisplatin in patients with advanced non-small-cell lung cancer: a phase II study. J Clin Oncol. 1998 Nov; 16(11):3524-7. PMID: 9817270.
      View in: PubMed
    231. Rishi AK, Yu M, Tsai-Wu JJ, Belani CP, Fontana JA, Baker DL, Periasamy M, Hussain A. Gene amplification and transcriptional upregulation of the sarco/endoplasmic reticulum Ca2+ transport ATPase in thapsigargin-resistant hamster smooth muscle cells. Nucleic Acids Res. 1998 Oct 01; 26(19):4529-37. PMID: 9742259; PMCID: PMC147867.
    232. Kassis ES, Belani CP, Ferson PF, Keenan RJ, Luketich JD. Hodgkin's disease presenting with a bronchoesophageal fistula. Ann Thorac Surg. 1998 Oct; 66(4):1409-10. PMID: 9800846.
      View in: PubMed
    233. Belani CP. Single agents in the second-line treatment of non-small cell lung cancer. Semin Oncol. 1998 Jun; 25(3 Suppl 8):10-4. PMID: 9704670.
      View in: PubMed
    234. Greenberger JS, Bahri S, Jett J, Belani C, Kalend A, Epperly M. Considerations in optimizing radiation therapy for non-small cell lung cancer. Chest. 1998 Jan; 113(1 Suppl):46S-52S. PMID: 9438690.
      View in: PubMed
    235. Belani CP, Ramanathan RK. Combined-modality treatment of locally advanced non-small cell lung cancer: incorporation of novel chemotherapeutic agents. Chest. 1998 Jan; 113(1 Suppl):53S-60S. PMID: 9438691.
      View in: PubMed
    236. Belani CP, Pajeau TS, Bennett CL. Treating malignant pleural effusions cost consciously. Chest. 1998 Jan; 113(1 Suppl):78S-85S. PMID: 9438695.
      View in: PubMed
    237. Belani CP. Paclitaxel/carboplatin in the treatment of non-small-cell lung cancer. Oncology (Williston Park). 1998 Jan; 12(1 Suppl 2):74-9. PMID: 9516617.
      View in: PubMed
    238. Luketich JD, Schauer P, Urso K, Townsend DW, Belani CP, Cidis Meltzer C, Ferson PF, Keenan RJ. Minimally invasive surgical biopsy confirms PET findings in esophageal cancer. Surg Endosc. 1997 Dec; 11(12):1213-5. PMID: 9373297.
      View in: PubMed
    239. Belani CP, Luketich JD, Landreaneau RJ, Kim R, Ramanathan RK, Day R, Ferson PF, Keenan RJ, Posner M, Seeger J, Lembersky B. Efficacy of cisplatin, 5-fluorouracil, and paclitaxel regimen for carcinoma of the esophagus. Semin Oncol. 1997 Dec; 24(6 Suppl 19):S19-89-S19-92. PMID: 9427275.
      View in: PubMed
    240. Luketich JD, Schauer PR, Meltzer CC, Landreneau RJ, Urso GK, Townsend DW, Ferson PF, Keenan RJ, Belani CP. Role of positron emission tomography in staging esophageal cancer. Ann Thorac Surg. 1997 Sep; 64(3):765-9. PMID: 9307471.
      View in: PubMed
    241. Ramanathan RK, Belani CP. Chemotherapy for advanced non-small cell lung cancer: past, present, and future. Semin Oncol. 1997 Aug; 24(4):440-54. PMID: 9280224.
      View in: PubMed
    242. Belani CP. Docetaxel in combination with platinums in patients with advanced non-small-cell lung cancer. Oncology (Williston Park). 1997 Aug; 11(8 Suppl 8):42-5. PMID: 9364542.
      View in: PubMed
    243. Belani CP, Aisner J, Bahri S, Jett J, Day R, Capazolli MJ, Hiponia D, Engstrom C. Chemoradiotherapy in non-small cell lung cancer: paclitaxel/carboplatin/radiotherapy in regionally advanced disease. Semin Oncol. 1996 Dec; 23(6 Suppl 16):113-6. PMID: 9007136.
      View in: PubMed
    244. Belani CP, Aisner J, Hiponia D, Ramanathan R. Paclitaxel and carboplatin in metastatic non-small cell lung cancer: preliminary results of a phase I study. Semin Oncol. 1996 Oct; 23(5 Suppl 12):19-21. PMID: 8941406.
      View in: PubMed
    245. Ramanathan RK, Reddy VV, Holbert JM, Belani CP. Pulmonary infiltrates following administration of paclitaxel. Chest. 1996 Jul; 110(1):289-92. PMID: 8681647.
      View in: PubMed
    246. Ramanathan RK, Belani CP. Transient pulmonary infiltrates: a hypersensitivity reaction to paclitaxel. Ann Intern Med. 1996 Jan 15; 124(2):278. PMID: 8534016.
      View in: PubMed
    247. Aisner J, Belani CP, Kearns C, Conley B, Hiponia D, Engstrom C, Zuhowski E, Egorin MJ. Feasibility and pharmacokinetics of paclitaxel, carboplatin, and concurrent radiotherapy for regionally advanced squamous cell carcinoma of the head and neck and for regionally advanced non-small cell lung cancer. Semin Oncol. 1995 Oct; 22(5 Suppl 12):17-21. PMID: 7481856.
      View in: PubMed
    248. Kearns CM, Belani CP, Erkmen K, Zuhowski M, Hiponia D, Zacharski D, Engstrom C, Ramanathan R, Trenn MR, Aisner J, et al. Pharmacokinetics of paclitaxel and carboplatin in combination. Semin Oncol. 1995 Oct; 22(5 Suppl 12):1-4; discussion 5-7. PMID: 7481850.
      View in: PubMed
    249. Doyle LA, Ross DD, Ordonez JV, Yang W, Gao Y, Tong Y, Belani CP, Gutheil JC. An etoposide-resistant lung cancer subline overexpresses the multidrug resistance-associated protein. Br J Cancer. 1995 Sep; 72(3):535-42. PMID: 7669558; PMCID: PMC2033885.
    250. Belani CP, Aisner J, Hiponia D, Engstrom C. Paclitaxel and carboplatin with and without filgrastim support in patients with metastatic non-small cell lung cancer. Semin Oncol. 1995 Aug; 22(4 Suppl 9):7-12. PMID: 7544028.
      View in: PubMed
    251. Hainsworth JD, Levitan N, Wampler GL, Belani CP, Seyedsadr MS, Randolph J, Schacter LP, Greco FA. Phase II randomized study of cisplatin plus etoposide phosphate or etoposide in the treatment of small-cell lung cancer. J Clin Oncol. 1995 Jun; 13(6):1436-42. PMID: 7751890.
      View in: PubMed
    252. Vokes EE, Rosenberg RK, Jahanzeb M, Craig JB, Gralla RJ, Belani CP, Jones SE, Bigley JW, Hohneker JA. Multicenter phase II study of weekly oral vinorelbine for stage IV non-small-cell lung cancer. J Clin Oncol. 1995 Mar; 13(3):637-44. PMID: 7533824.
      View in: PubMed
    253. White CS, Haramati LB, Elder KH, Karp J, Belani CP. Carcinoma of the lung in HIV-positive patients: findings on chest radiographs and CT scans. AJR Am J Roentgenol. 1995 Mar; 164(3):593-7. PMID: 7863877.
      View in: PubMed
    254. Vokes EE, Rosenberg R, Jahanzeb M, Craig J, Gralla R, Belani C, Jones S, Bigley J, Hohneker J. Oral vinorelbine (Navelbine) in the treatment of advanced non-small cell lung cancer: a preliminary report. Semin Oncol. 1994 Oct; 21(5 Suppl 10):35-8; discussion 38-41. PMID: 7973767.
      View in: PubMed
    255. Belani CP, Aisner J. Combined chemotherapy and radiation in locally advanced non-small cell lung cancer. Semin Oncol. 1994 Jun; 21(3 Suppl 6):79-90. PMID: 8052878.
      View in: PubMed
    256. Flores JF, Rude RK, Chapman RA, Belani CP, Chang AY, Pritchard JD, Hoff JV. Evaluation of a 24-hour infusion of etidronate disodium for the treatment of hypercalcemia of malignancy. Cancer. 1994 May 15; 73(10):2527-34. PMID: 8174049.
      View in: PubMed
    257. Hollen PJ, Gralla RJ, Kris MG, Cox C, Belani CP, Grunberg SM, Crawford J, Neidhart JA. Measurement of quality of life in patients with lung cancer in multicenter trials of new therapies. Psychometric assessment of the Lung Cancer Symptom Scale. Cancer. 1994 Apr 15; 73(8):2087-98. PMID: 8156514.
      View in: PubMed
    258. Bleehen NM, Ball D, Belani CP, Bishop J, Douillard JY, Cox JD, Johnson DH, Le Chevalier T, Saunders MI, Shaw E, et al. Combined radiation and chemotherapy for unresectable non-small cell lung carcinoma. Lung Cancer. 1994 Mar; 10 Suppl 1:S19-23. PMID: 8087510.
      View in: PubMed
    259. Belani CP, Doyle LA, Aisner J. Etoposide: current status and future perspectives in the management of malignant neoplasms. Cancer Chemother Pharmacol. 1994; 34 Suppl:S118-26. PMID: 8070020.
      View in: PubMed
    260. Belani CP. Multimodality management of regionally advanced non-small-cell lung cancer. Semin Oncol. 1993 Aug; 20(4):302-14. PMID: 8393590.
      View in: PubMed
    261. Belani CP, Aisner J. Combined-modality therapies for non-small cell lung cancer. Ann Oncol. 1992 Aug; 3 Suppl 3:3-10. PMID: 1327080.
      View in: PubMed
    262. Kruter F, Eisenberger M, Sinibaldi V, Engstrom C, Jacobs M, Abrams J, Belani C, Gray W, Krasnow S. Phase II trial of 5 day continuous intravenous infusion of 6-thioguanine in patients with recurrent and metastatic squamous cell carcinoma of the head and neck. Invest New Drugs. 1992 Jul; 10(2):89-91. PMID: 1500270.
      View in: PubMed
    263. Belani CP, Aisner J. Therapy for small cell and non-small cell lung cancer. Curr Opin Oncol. 1990 Apr; 2(2):334-44. PMID: 1965630.
      View in: PubMed
    264. Belani CP, Egorin MJ, Abrams JS, Hiponia D, Eisenberger M, Aisner J, Van Echo DA. A novel pharmacodynamically based approach to dose optimization of carboplatin when used in combination with etoposide. J Clin Oncol. 1989 Dec; 7(12):1896-902. PMID: 2555452.
      View in: PubMed
    265. Whitley NO, Belani CP, Aisner J, Forrest A, Whitley J. Tumor volume and treatment outcome in small cell lung carcinoma. Invest Radiol. 1989 Aug; 24(8):581-4. PMID: 2550385.
      View in: PubMed
    266. Belani CP, Eisenberger MA, Gray WC. Preliminary experience with chemotherapy in advanced salivary gland neoplasms. Med Pediatr Oncol. 1988; 16(3):197-202. PMID: 2837623.
      View in: PubMed
    267. Belani CP, Eisenberger M, Van Echo D, Hiponia D, Aisner J. Phase II study of caracemide in advanced or recurrent non-small cell lung cancer. Cancer Treat Rep. 1987 Nov; 71(11):1099-100. PMID: 2824047.
      View in: PubMed
    Belani's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description
    Physical Neighbors Expand Description
    _